

Irene Teresa Molina MartÃ-nez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777646/publications.pdf>

Version: 2024-02-01

49
papers

1,570
citations

279487
23
h-index

315357
38
g-index

55
all docs

55
docs citations

55
times ranked

2049
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce <i>in vitro</i> hyperosmolar stress in dry eye treatments. Journal of Liposome Research, 2023, 33, 117-128.	1.5	2
2	Validation of a Rapid and Easy-to-Apply Method to Simultaneously Quantify Co-Loaded Dexamethasone and Melatonin PLGA Microspheres by HPLC-UV: Encapsulation Efficiency and In Vitro Release. Pharmaceutics, 2022, 14, 288.	2.0	8
3	Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection. International Journal of Pharmaceutics, 2022, 623, 121948.	2.6	3
4	Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment. Pharmaceutics, 2022, 14, 1405.	2.0	4
5	Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. Expert Opinion on Drug Delivery, 2021, 18, 1-29.	2.4	36
6	A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies. Pharmaceutics, 2021, 14, 50.	1.7	9
7	Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies. Pharmaceutics, 2021, 13, 228.	2.0	16
8	Thermo-Responsive PLGA-PEG-PLGA Hydrogels as Novel Injectable Platforms for Neuroprotective Combined Therapies in the Treatment of Retinal Degenerative Diseases. Pharmaceutics, 2021, 13, 234.	2.0	24
9	Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases. Drug Delivery and Translational Research, 2021, 11, 566-580.	3.0	8
10	Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments. Experimental Eye Research, 2021, 211, 108723.	1.2	12
11	Gelatin Nanoparticles-HPMC Hybrid System for Effective Ocular Topical Administration of Antihypertensive Agents. Pharmaceutics, 2020, 12, 306.	2.0	23
12	Trojan Microparticles Potential for Ophthalmic Drug Delivery. Current Medicinal Chemistry, 2020, 27, 570-582.	1.2	4
13	Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers. Polymers, 2019, 11, 1213.	2.0	6
14	Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. Journal of Controlled Release, 2019, 297, 26-38.	4.8	57
15	Osmoprotectants in Hybrid Liposome/HPMC Systems as Potential Glaucoma Treatment. Polymers, 2019, 11, 929.	2.0	20
16	Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects. International Journal of Molecular Sciences, 2019, 20, 1655.	1.8	19
17	Microspheres as intraocular therapeutic tools in chronic diseases of the optic nerve and retina. Advanced Drug Delivery Reviews, 2018, 126, 127-144.	6.6	28
18	Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation. Experimental Eye Research, 2018, 167, 118-121.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Novel liposome-based and in situ gelling artificial tear formulation for dry eye disease treatment. Contact Lens and Anterior Eye, 2018, 41, 93-96.	0.8	41
20	Design and Application of a Computer Tool to Evaluate the Goodness of Fit for Tests Designed to Be Self-Taught. Proceedings (mdpi), 2018, 2, .	0.2	0
21	Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film. Polymers, 2018, 10, 425.	2.0	28
22	Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice. Molecular Vision, 2018, 24, 733-745.	1.1	15
23	Six month delivery of GDNF from PLGA/vitamin E biodegradable microspheres after intravitreal injection in rabbits. European Journal of Pharmaceutical Sciences, 2017, 103, 19-26.	1.9	29
24	Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. Journal of Controlled Release, 2017, 266, 187-197.	4.8	29
25	Novel technologies for the delivery of ocular therapeutics in glaucoma. Journal of Drug Delivery Science and Technology, 2017, 42, 181-192.	1.4	17
26	Novel anti-inflammatory liposomal formulation for the pre-ocular tear film: InÂvitro and exÂvivo functionality studies in corneal epithelial cells. Experimental Eye Research, 2017, 154, 79-87.	1.2	12
27	Ketorolac Administration Attenuates Retinal Ganglion Cell Death After Axonal Injury. , 2016, 57, 1183.		16
28	Novel Water-Soluble Mucoadhesive Carbosilane Dendrimers for Ocular Administration. Molecular Pharmaceutics, 2016, 13, 2966-2976.	2.3	50
29	Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases. Drug Delivery and Translational Research, 2016, 6, 686-707.	3.0	27
30	Optimising the controlled release of dexamethasone from a new generation of PLGA-based microspheres intended for intravitreal administration. European Journal of Pharmaceutical Sciences, 2016, 92, 287-297.	1.9	37
31	Investigating the Discriminatory Power of BCS-Biowaiver <i>in Vitro</i> Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Molecular Pharmaceutics, 2015, 12, 3167-3174.	2.3	26
32	The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Progress in Retinal and Eye Research, 2014, 42, 27-43.	7.3	96
33	Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. Investigative Ophthalmology and Visual Science, 2014, 55, 7839-7847.	3.3	42
34	Hybrid Formulations of Liposomes and Bioadhesive Polymers Improve the Hypotensive Effect of the Melatonin Analogue 5-MCA-NAT in Rabbit Eyes. PLoS ONE, 2014, 9, e110344.	1.1	29
35	Nano and microtechnologies for ophthalmic administration, an overview. Journal of Drug Delivery Science and Technology, 2013, 23, 75-102.	1.4	31
36	Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation. International Journal of Pharmaceutics, 2012, 436, 545-554.	2.6	23

#	ARTICLE	IF	CITATIONS
37	Synthesis and fluorescent properties of cationic carbosilane dendrimers containing eugenol linkers for their use in biomedical applications. New Journal of Chemistry, 2012, 36, 360-370.	1.4	12
38	Interfacial Interaction between Transmembrane Ocular Mucins and Adhesive Polymers and Dendrimers Analyzed by Surface Plasmon Resonance. Pharmaceutical Research, 2012, 29, 2329-2340.	1.7	56
39	The Use of Mucoadhesive Polymers to Enhance the Hypotensive Effect of a Melatonin Analogue, 5-MCA-NAT, in Rabbit Eyes. , 2011, 52, 1507.		21
40	Comparison of the In Vitro Tolerance and In Vivo Efficacy of Traditional Timolol Maleate Eye Drops versus New Formulations with Bioadhesive Polymers. , 2011, 52, 3548.		28
41	Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. Journal of Controlled Release, 2011, 156, 92-100.	4.8	89
42	Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT. Experimental Eye Research, 2009, 88, 504-511.	1.2	26
43	Biocompatibility of elastin-like polymer poly(VPAVG) microparticles:in vitro andin vivo studies. Journal of Biomedical Materials Research - Part A, 2006, 78A, 343-351.	2.1	86
44	Population pharmacokinetics of gentamicin in premature newborns. Journal of Antimicrobial Chemotherapy, 2006, 58, 372-379.	1.3	46
45	Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release. Journal of Controlled Release, 2005, 102, 113-122.	4.8	211
46	Biodegradable ibuprofen-loaded PLGA microspheres for intraarticular administration. International Journal of Pharmaceutics, 2004, 279, 33-41.	2.6	99
47	Sterilized ibuprofen-loaded poly(D,L-lactide-co-glycolide) microspheres for intra-articular administration: effect of γ -irradiation and storage. Journal of Microencapsulation, 2004, 21, 653-665.	1.2	29
48	Pharmacokinetics of intravenous luxabendazole in rabbits: influence of the enterohepatic circulation. , 1998, 19, 341-347.		4
49	Bioavailability and Bioequivalence of Two Formulations of Etodolac (Tablets and Suppositories). Journal of Pharmaceutical Sciences, 1993, 82, 211-213.	1.6	7